Profile: Progenics Pharmaceuticals Inc (PGNX.OQ)
26 Mar 2015
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is a medicine developing company. The Company is engaged in developing medicines for oncology. Its focus for Progenics is targeted therapeutics and imaging agents. The Company’s clinical development efforts center on late-stage oncology assets. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra.
PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. In a Phase 2 open-label, multicenter clinical trial to assess anti-tumor activity, tolerability and safety, the Company has completed enrollment in an original cohort of chemotherapy refractory patients with metastatic castration-resistant prostate cancer (mCRPC) and are conducting a second cohort of chemotherapy-naive patients.
1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer, including metastases in other soft tissue and bone. It has completed a multicentered Phase 2 study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer scheduled for radical prostectomy.
Azedra is a Phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. Azedra has Orphan Drug designation and Fast Track status in the United States for pheochromocytoma and paraganglioma.
Relistor, a treatment for opioid-induced constipation (OIC), decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. Relistor subcutaneous injection is approved for sale in the United States, European Union, Canada, Australia and elsewhere in pre-filled syringes. Under Progenics’s License Agreement, Salix is responsible for developing and commercializing Relistor, including completing clinical development necessary to support regulatory marketing approvals for potential new indications (such as OIC in patients with chronic, non-cancer pain) and formulations of the drug (such as an oral formulation of methylnaltrexone, the active ingredient in Relistor).
The Company competes with Cubist Pharmaceuticals, Sucampo Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Nektar Therapeutics-AstraZeneca PLC; Shionogi & Co.; Theravance, Inc.; Mundipharma International Limited; Johnson & Johnson’s subsidiary Janssen Biotech, Inc.; Medivation, Inc.; Algeta ASA and Jazz Pharmaceuticals.
Progenics Pharmaceuticals Inc
777 Old Saw Mill River Road
TARRYTOWN NY 10591